Aytu BioPharma (AYTU) Stock Price, News & Analysis

Company Overview

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms. The company also offers NeoProfen (ibuprofen lysine injection) for the closure of patent ductus arteriosus in premature infants and markets an FDA-authorized rapid antigen COVID-19 self-test under license. Aytu’s products are generally distributed through specialty pharmacies, hospital networks and national wholesale distributors across the United States.

Under the leadership of President and Chief Executive Officer Josh Disbrow, Aytu continues to explore licensing partnerships and in-licensing opportunities to expand its pipeline. In addition to its commercial business, the company holds exclusive rights to clinical-stage candidates addressing chronic kidney disease and other orphan indications. Aytu’s management team brings experience in life sciences finance, regulatory affairs and commercial operations as it seeks to grow both its therapeutic and diagnostic offerings and extend its reach through strategic collaborations.

Key Stats

• Today's Range: $2.32 to $2.42
• 50-Day Range: $1.71 to $2.51
• 52-Week Range: $0.95 to $2.82
• Volume: 62,445 shs
• Average Volume: 389,577 shs
• Market Capitalization: $23.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.17
• Consensus Rating: Hold

Aytu BioPharma Stock Analysis - MarketRank™

Aytu BioPharma scored higher than 67% of companies evaluated by MarketBeat, and ranked 322nd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Hold

Consensus Rating

Aytu BioPharma has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 3 buy ratings, no hold ratings, and 2 sell ratings.

Upside Potential

Aytu BioPharma has a consensus price target of $9.17, representing about 288.4% upside from its current price of $2.36.

Amount of Analyst Coverage

Aytu BioPharma has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Aytu BioPharma is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aytu BioPharma is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aytu BioPharma has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.97% of the float of Aytu BioPharma has been sold short.

Short Interest Ratio / Days to Cover

Aytu BioPharma has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aytu BioPharma has recently increased by 30.84%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aytu BioPharma does not currently pay a dividend.

Dividend Growth

Aytu BioPharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.4 / 5
• Environmental Score: -2.45

Percentage of Shares Shorted

6.97% of the float of Aytu BioPharma has been sold short.

Short Interest Ratio / Days to Cover

Aytu BioPharma has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aytu BioPharma has recently increased by 30.84%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: -0.13

News Sentiment

Aytu BioPharma has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Aytu BioPharma this week, compared to 1 article on an average week.

Search Interest

16 people have searched for AYTU on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Aytu BioPharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aytu BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.60% of the stock of Aytu BioPharma is held by insiders.

Percentage Held by Institutions

Only 33.49% of the stock of Aytu BioPharma is held by institutions.

AYTU Stock Analysis - Frequently Asked Questions

How have AYTU shares performed this year?

Aytu BioPharma's stock was trading at $1.70 on January 1st, 2025. Since then, AYTU stock has increased by 38.8% and is now trading at $2.36.

How were Aytu BioPharma's earnings last quarter?

Aytu BioPharma Inc. (NASDAQ:AYTU) posted its earnings results on Tuesday, September, 23rd. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.02) by $0.24. The company had revenue of $15.14 million for the quarter, compared to the consensus estimate of $18.06 million. Aytu BioPharma had a negative net margin of 20.43% and a positive trailing twelve-month return on equity of 13.77%.
Read the conference call transcript.

When did Aytu BioPharma's stock split?

Aytu BioPharma shares reverse split on the morning of Tuesday, August 29th 2017.The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Aytu BioPharma?

Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aytu BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aytu BioPharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), GE Aerospace (GE), CymaBay Therapeutics (CBAY) and Adobe (ADBE).

Company Calendar

• Last Earnings: 9/23/2025
• Today: 10/21/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AYTU
• CIK: 1385818
• Web: aytubio.com
• Phone: (720) 437-6580
• Fax: N/A
• Employees: 160
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Aytu BioPharma: $9.17
• High Price Target: $12.50
• Low Price Target: $7.00
• Potential Upside/Downside: +289.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.56 million
• Net Margins: -20.43%
• Pretax Margin: -20.71%
• Return on Equity: 13.77%
• Return on Assets: 3.28%

Debt

• Debt-to-Equity Ratio: 0.57
• Current Ratio: 1.26
• Quick Ratio: 1.07

Sales & Book Value

• Annual Sales: $66.38 million
• Price / Sales: 0.35
• Cash Flow: $0.39 per share
• Price / Cash Flow: 6.10
• Book Value: $2.11 per share
• Price / Book: 1.12

Miscellaneous

• Outstanding Shares: 9,910,000
• Free Float: 9,555,000
• Market Cap: $23.34 million
• Optionable: Not Optionable
• Beta: 0.27